David A. Fox

Michigan Medicine — United States

Immunology and Microbiology · Life Sciences

68h-index17.4kcitations339works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and B-cell Immunology(75), Rheumatoid Arthritis Research and Therapies(54), Monoclonal and Polyclonal Antibodies Research(53), Immune Cell Function and Interaction(45), Systemic Lupus Erythematosus Research(44)

Publications337 total

Soluble CD13 in systemic sclerosis: clinical observations and transcriptomic insights from peripheral blood
Arthritis Research & Therapy·2026Open Access
Spatial transcriptomics uncovers lipid metabolic dysregulation driving immune-stroma crosstalk in Sjögren's Disease
EBioMedicine·2025Open Access
Designer Benzodiazepines and Related Novel Psychoactive Substances (NPS) in Seized Tablets in Ireland 2019-2025
Emerging Trends in Drugs Addictions and Health·2025Open Access
Author Reply
Value in Health·2025
207 Brentuximab vedotin treatment reduces inflammatory gene expression by T and B cells in scleroderma skin, leading to reduced expression of pro-fibrotic markers
Journal of Investigative Dermatology·2025
Decentralizing genetic testing for biodiversity monitoring and biosurveillance with the Nucleic Acid Barcode Identification Tool (NABIT)
Frontiers in Conservation Science·2025Open Access
Bereavement Experiences Among Parents of Children With Spinal Muscular Atrophy Type 1
Journal of Pain and Symptom Management·2025· 1 cited
Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular Atrophy
Value in Health·2025· 4 cited
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Arthritis & Rheumatology·2025· 12 citedOpen Access
OP0149 ANTI-CARBAMYLATED PROTEIN ANTIBODIES INHIBIT HISTONE DEGRADATION AND CONTRIBUTE TO BONE EROSION IN RHEUMATOID ARTHRITIS
Annals of the Rheumatic Diseases·2025Open Access
Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus
Arthritis & Rheumatology·2025· 1 citedOpen Access
Soluble CD13 is a potential mediator of neutrophil-induced thrombogenic inflammation in SARS-CoV-2 infection
JCI Insight·2025· 4 citedOpen Access
CD6 in Human Disease
Cells·2025· 5 citedOpen Access
Ligands of CD6: roles in the pathogenesis and treatment of cancer
Frontiers in Immunology·2025· 2 citedOpen Access
Recurrent hepatocelluar carcinoma - pathway to transplant
HPB·2025
Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis
Arthritis & Rheumatology·2024· 12 citedOpen Access
PT15 Machine Learning Vs Traditional Statistics: Developing a Novel Proxy for HPV-Associated LA SCCHN
Value in Health·2024
Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network
Lara D. Veeken·2024· 6 citedOpen Access
Abstract 6025: Discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display
Cancer Research·2024
Rheumatoid arthritis – the challenge of heterogeneity
Current Opinion in Rheumatology·2024· 1 cited
page 1 of 17Next →

Frequent Co-authors

Steven K. Lundy(6), Judith Endres(6), Carmelo Carmona‐Rivera(5), Mariana J. Kaplan(5), Ellis L. Reinherz(4), Sujata Sarkar(4), Dinesh Khanna(4), M. Asif Amin(4), Rebecca E. Hussey(3), Stuart F. Schlossman(3), Laura Tesmer(3), Phillip L. Campbell(3), Nicholas Chiorazzi(3), David H. Katz(3), Kevin C. Chung(3), Julie M. Jorns(3), Jeffrey H. Ruth(3), Laura A. Cooney(3), Alison M. Gizinski(2), Srilakshmi Yalavarthi(2)